Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.
Last trade$0.7354
Day change-$0.0046 (-0.62%)
Day range$0.723 – $0.757
Volume4,273,830
Market cap$37M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$37.12M
Price / earnings
—
Price / book
2.09×
Price / sales
1.06×
EV / sales
1.18×
EV / EBITDA
-0.89×
Profitability
Earnings per share
-$1.02
Return on assets
-87.6%
Return on equity
-288.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.08×
Current ratio
2.55×
Quick ratio
1.51×
Cash ratio
0.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RPID, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$8.05M
$8M
$11.28M
$7.84M
$7.26M
$7.21M
$8.22M
$7.6M
Cost of revenue
$6.84M
$7.63M
$11.61M
$7.14M
$6.99M
$6.8M
$7.24M
$6.98M
Gross profit
$1.21M
$371K
-$328K
$696K
$275K
$404K
$981K
$622K
Selling, general and administrative
$10.2M
$10.86M
$8.66M
$8.54M
$9.19M
$8.44M
$7.81M
$9.05M
Research and development
$3.33M
$3.36M
$3.22M
$3.53M
$3.23M
$3.62M
$3.4M
$3.61M
Total operating expenses
$13.53M
$14.22M
$11.88M
$12.07M
$12.42M
$12.07M
$11.21M
$12.66M
Operating income
-$12.32M
-$13.85M
-$12.21M
-$11.37M
-$12.15M
-$11.66M
-$10.23M
-$12.04M
Interest expense
-$646K
-$639K
-$673K
-$393K
-$12K
-$12K
-$12K
-$11K
Income before taxes
-$12.88M
-$14.27M
-$12.48M
-$11.5M
-$11.85M
-$11.26M
-$9.68M
-$11.31M
Income taxes
$45K
$8K
$14K
$8K
$11K
$7K
-$9K
$13K
Net income
-$12.92M
-$14.28M
-$12.5M
-$11.51M
-$11.86M
-$11.26M
-$9.67M
-$11.32M
Net income attributable to common shareholders
-$12.92M
-$14.28M
-$12.5M
-$11.51M
-$11.86M
-$11.26M
-$9.67M
-$11.32M
EBITDA
-$11.65M
-$13.15M
-$11.42M
-$10.57M
-$11.34M
-$10.81M
-$9.36M
-$11.18M
Basic earnings per share
-$0.27
-$0.31
-$0.28
-$0.26
-$0.27
-$0.26
-$0.22
-$0.26
Diluted earnings per share
-$0.27
-$0.31
-$0.28
-$0.26
-$0.27
-$0.26
-$0.22
-$0.26
Recent news
Company coverage with links to the original publishers.
Rapid Micro Biosystems reported a Q3 loss of $0.22 per share, missing EPS expectations by 10% despite beating revenue estimates at $9.53 million. The company has underperformed the market significantly, down 77.6% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market.
DarioHealth Corp. (DRIO) reported a quarterly loss of $0.44 per share, beating consensus estimates of $0.51 loss, with a 13.73% earnings surprise. Revenues reached $5.31 million, slightly exceeding expectations. However, the stock has plummeted 81.3% year-to-date compared to the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Pulse Biosciences reported a Q3 loss of $0.32 per share, beating EPS estimates but missing revenue expectations with $0.4 million versus consensus estimates. The company has significantly outperformed the S&P 500 this year with a 315.6% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Tactile Systems Technology (TCMD) beat EPS estimates with $0.31 per share versus consensus of $0.30, but missed revenue expectations at $91.86 million. The stock has underperformed the market by 20.6% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 42% of Zacks industries.
Rapid Micro Biosystems (RPID) announced a pricing of an underwritten offering of 3.58 million shares of Class A common stock at $1.955 per share, combined with Series A and Series B warrants. Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with potential additional proceeds of $21.7 million if all warrants are exercised. The offering is expected to close on May 20, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.